Review

Immunotherapeutic approaches against Staphylococcus aureus

† Author for correspondence

Email the corresponding author at n.j.verkaik@erasmusmc.nl

Erasmus Medical Center, Department of Medical Microbiology & Infectious Diseases, ‘s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

Search for more papers by this author

Alex van Belkum

Erasmus Medical Center, Department of Medical Microbiology & Infectious Diseases, ‘s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands

BioMérieux, 3 route de Port Michaud, La Balme-Les-Grottes, 38390, France

Search for more papers by this author

Published Online:13 Sep 2011https://doi.org/10.2217/imt.11.84

View article

Abstract

Staphylococcus aureus is a major cause of life-threatening infections such as bacteremia and endocarditis. Unfortunately, many strains of this bacterial species have become resistant to certain antibiotics, including methicillin and amoxicillin. These strains are known as methicillin-resistant S. aureus (MRSA). Therefore, the prophylactic and therapeutic potential of antistaphylococcal vaccines is currently being explored with priority. In animal models, (passive) immunization with (antibodies directed against) certain S. aureus surface components, staphylococcal toxins and capsular polysaccharides protects against S. aureus colonization or infection. However, immunization studies performed in humans show less promising results. So far, not a single antistaphylococcal vaccine successfully passed clinical trials. This article focuses on the results that were obtained with immunotherapeutic approaches directed against S. aureus in animal and human studies. In addition, it is discussed whether effective immunization approaches against S. aureus are feasible in humans.

Keywords:

Papers of special note have been highlighted as: ▪ of interest

Bibliography

1 Ogston A. Micrococcus poisoning. J. Anat. Physiol.17,24–58 (1882).Medline, CAS, Google Scholar
2 Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis.5,751–762 (2005).Crossref, Medline, Google Scholar
3 van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis.199,1820–1826 (2009).Crossref, Medline, Google Scholar
4 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N. Engl. J. Med.344,11–16 (2001).Crossref, Medline, CAS, Google Scholar
5 Toshkova K, Annemuller C, Akineden O, Lammler C. The significance of nasal carriage of Staphylococcus aureus as risk factor for human skin infections. FEMS Microbiol. Lett.202,17–24 (2001).Crossref, Medline, CAS, Google Scholar
6 Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch. Intern. Med.163,2066–2072 (2003).Crossref, Medline, Google Scholar
7 Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection.39,141–147 (2011).Crossref, Medline, CAS, Google Scholar
8 Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis.52,113–122 (2005).Crossref, Medline, Google Scholar
9 Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA298,1763–1771 (2007).Crossref, Medline, CAS, Google Scholar
10 Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet1,904–907 (1963).Crossref, Medline, CAS, Google Scholar
11 Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg. Infect. Dis.13,1840–1846 (2007).Crossref, Medline, Google Scholar
12 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC (2010).Google Scholar
13 Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin. Infect. Dis.46,668–674 (2008).Crossref, Medline, CAS, Google Scholar
14 Bode LG, Kluytmans JA, Wertheim HF et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus.N. Engl. J. Med.362,9–17 (2010).▪ Shows that the number of surgical-site Staphylococcus aureus infections acquired in the hospital can be reduced by rapid screening and decolonizing of nasal carriers of S. aureus on admission.Crossref, Medline, CAS, Google Scholar
15 Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother.41,11–18 (1998).Crossref, Medline, CAS, Google Scholar
16 Projan SJ, Nesin M, Dunman PM. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin Pharmacol.6,473–479 (2006).Crossref, Medline, CAS, Google Scholar
17 Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int. J. Med. Microbiol.300,402–410 (2010).Crossref, Medline, Google Scholar
18 Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol. Ther.10,1049–1059 (2010).Crossref, Medline, CAS, Google Scholar
19 Garcia-Lara J, Foster SJ. Anti-Staphylococcus aureus immunotherapy: current status and prospects. Curr. Opin Pharmacol.9,552–557 (2009).Crossref, Medline, CAS, Google Scholar
20 Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North. Am.23,153–171 (2009).Crossref, Medline, Google Scholar
21 Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus.Trends Microbiol.6,484–488 (1998).Crossref, Medline, CAS, Google Scholar
22 Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol.48,585–617 (1994).Crossref, Medline, CAS, Google Scholar
23 Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am. Heart J.147,593–598 (2004).Crossref, Medline, CAS, Google Scholar
24 Holtfreter S, Roschack K, Eichler P et al.Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J. Infect. Dis.193,1275–1278 (2006).Crossref, Medline, CAS, Google Scholar
25 Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus.Clin. Microbiol. Rev.13,16–34 (2000).Crossref, Medline, CAS, Google Scholar
26 Stolz SJ, Davis JP, Vergeront JM et al. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J. Infect. Dis.151,883–889 (1985).Crossref, Medline, CAS, Google Scholar
27 Bhakdi S, Tranum-Jensen J. α-toxin of Staphylococcus aureus. Microbiol. Rev.55,733–751 (1991).Crossref, Medline, CAS, Google Scholar
28 Clarke SR, Brummell KJ, Horsburgh MJ et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis.193,1098–1108 (2006).Crossref, Medline, CAS, Google Scholar
29 Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun.74,2215–2223 (2006).Crossref, Medline, CAS, Google Scholar
30 Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus.Proc. Natl Acad. Sci. USA103,16942–16947 (2006).Crossref, Medline, CAS, Google Scholar
31 Ebert T, Smith S, Pancari G et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum. Antibodies19,113–128 (2010).Crossref, Medline, CAS, Google Scholar
32 Josefsson E, Hartford O, O’Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis.184,1572–1580 (2001).Crossref, Medline, CAS, Google Scholar
33 Vernachio J, Bayer AS, Le T et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother.47,3400–3406 (2003).Crossref, Medline, CAS, Google Scholar
34 Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun.76,5738–5744 (2008).Crossref, Medline, CAS, Google Scholar
35 Vernachio JH, Bayer AS, Ames B et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother.50,511–518 (2006).Crossref, Medline, CAS, Google Scholar
36 Schaffer AC, Solinga RM, Cocchiaro J et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun.74,2145–2153 (2006).Crossref, Medline, CAS, Google Scholar
37 Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J. Clin. Invest.101,2640–2649 (1998).Crossref, Medline, CAS, Google Scholar
38 Zhou H, Xiong ZY, Li HP, Zheng YL, Jiang YQ. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine24,4830–4837 (2006).Crossref, Medline, CAS, Google Scholar
39 Rennermalm A, Li YH, Bohaufs L et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine19,3376–3383 (2001).Crossref, Medline, CAS, Google Scholar
40 Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J. Exp. Med.207,1863–1870 (2010).▪ Shows that immunization of mice with a nontoxigenic protein A vaccine raised antibodies that blocked the virulence of staphylococci, promoted opsonophagocytic clearance and protected mice against challenge with highly virulent methicillin-resistant S. aureus strains.Crossref, Medline, CAS, Google Scholar
41 Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med.205,287–294 (2008).Crossref, Medline, Google Scholar
42 Kennedy AD, Bubeck Wardenburg J, Gardner DJ et al. Targeting of α-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis.202,1050–1058 (2010).Crossref, Medline, Google Scholar
43 Hume EB, Dajcs JJ, Moreau JM, O’Callaghan RJ. Immunization with α-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect. Immun.68,6052–6055 (2000).Crossref, Medline, CAS, Google Scholar
44 Adlam C, Ward PD, McCartney AC, Arbuthnott JP, Thorley CM. Effect immunization with highly purified α- and β-toxins on staphylococcal mastitis in rabbits. Infect. Immun.17,250–256 (1977).Crossref, Medline, CAS, Google Scholar
45 Nilsson IM, Verdrengh M, Ulrich RG, Bavari S, Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J. Infect. Dis.180,1370–1373 (1999).Crossref, Medline, CAS, Google Scholar
46 LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect. Immun.70,2278–2281 (2002).Crossref, Medline, CAS, Google Scholar
47 Lowell GH, Colleton C, Frost D et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun.64,4686–4693 (1996).Crossref, Medline, CAS, Google Scholar
48 Chang BS, Moon JS, Kang HM et al. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle. Vaccine26,2081–2091 (2008).Crossref, Medline, CAS, Google Scholar
49 Hu DL, Omoe K, Narita K, Cui JC, Shinagawa K, Nakane A. Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. Microbes Infect.8,2841–2848 (2006).Crossref, Medline, CAS, Google Scholar
50 Brown EL, Dumitrescu O, Thomas D et al. The Panton–Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect.15,156–164 (2009).Crossref, CAS, Google Scholar
51 Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun.64,1659–1665 (1996).Crossref, Medline, CAS, Google Scholar
52 Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun.65,4146–4151 (1997).Crossref, Medline, CAS, Google Scholar
53 McKenney D, Pouliot KL, Wang Y et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science284,1523–1527 (1999).Crossref, Medline, CAS, Google Scholar
54 Maira-Litran T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-β-(1–6)-glucosamine. Infect. Immun.73,6752–6762 (2005).Crossref, Medline, CAS, Google Scholar
55 Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol.48,1429–1449 (2003).Crossref, Medline, CAS, Google Scholar
56 Park J, Jagasia R, Kaufmann GF et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem. Biol.14,1119–1127 (2007).Crossref, Medline, CAS, Google Scholar
57 Glowalla E, Tosetti B, Kronke M, Krut O. Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect. Immun.77,2719–2729 (2009).Crossref, Medline, CAS, Google Scholar
58 Holtfreter S, Kolata J, Broker BM. Towards the immune proteome of Staphylococcus aureus – the anti-S. aureus antibody response. Int. J. Med. Microbiol.300,176–192 (2010).▪ Provides an up to date overview of the antibody response against S. aureus.Crossref, Medline, CAS, Google Scholar
59 Bloom B, Schelonka R, Kueser T et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr. Infect. Dis. J.24,858–866 (2005).Crossref, Medline, Google Scholar
60 DeJonge M, Burchfield D, Bloom B et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr.151,260–265, (2007).Crossref, Medline, CAS, Google Scholar
61 Weems JJ Jr, Steinberg JP, Filler S et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.50,2751–2755 (2006).Crossref, Medline, CAS, Google Scholar
62 Fattom A, Fuller S, Propst M et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine23,656–663 (2004).Crossref, Medline, CAS, Google Scholar
63 Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to Phase III clinical trials. Vaccine22,880–887 (2004).Crossref, Medline, CAS, Google Scholar
64 Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med.346,491–496 (2002).Crossref, Medline, Google Scholar
65 Verdier I, Durand G, Bes M et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J. Clin. Microbiol.45,725–729 (2007).Crossref, Medline, CAS, Google Scholar
66 von Eiff C, Taylor KL, Mellmann A et al. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus.Diagn. Microbiol. Infect. Dis.58,297–302 (2007).Crossref, Medline, CAS, Google Scholar
67 Benjamin DK, Schelonka R, White R et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol.26,290–295 (2006).Crossref, Medline, CAS, Google Scholar
68 Rupp ME, Holley HP Jr, Lutz J et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.51,4249–4254 (2007).Crossref, Medline, CAS, Google Scholar
69 Burnie JP, Matthews RC, Carter T et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun.68,3200–3209 (2000).Crossref, Medline, CAS, Google Scholar
70 Weisman LE, Thackray HM, Garcia-Prats JA et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob. Agents Chemother.53,2879–2886 (2009).Crossref, Medline, CAS, Google Scholar
71 Harro C, Betts R, Orenstein W et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin. Vaccine Immunol.17,1868–1874 (2010).Crossref, Medline, CAS, Google Scholar
72 Verkaik NJ, de Vogel CP, Boelens HA et al. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus.J. Infect. Dis.199,625–632 (2009).Crossref, Medline, Google Scholar
73 Verkaik NJ, Lebon A, de Vogel CP et al. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin. Microbiol. Infect.16,1312–1317 (2010).Crossref, Medline, CAS, Google Scholar
74 Kolata J, Bode L, Holtfreter S et al. Distinctive patterns in the human antibody response to S. aureus bacteremia revealed by a prospective and personalized immune proteome approach. Presented at: 14th International Symposium on Staphylococci and Staphylococcal Infections. Bath, UK, 6–9 September 2010.Google Scholar
75 Skurnik D, Merighi M, Grout M et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J. Clin. Invest.120,3220–3233 (2010).▪ Shows that when antibodies directed to capsular polysaccharides and poly-N-acetyl glucosamine are both present, they show potent interference in opsonophagocytic killing of S. aureus.Crossref, Medline, CAS, Google Scholar
76 Lindsay JA, Moore CE, Day NP et al. Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes. J. Bacteriol.188,669–676 (2006).Crossref, Medline, CAS, Google Scholar
77 Loughman A, Sweeney T, Keane FM, Pietrocola G, Speziale P, Foster TJ. Sequence diversity in the A domain of Staphylococcus aureus fibronectin-binding protein A. BMC Microbiol.8,74 (2008).Crossref, Medline, Google Scholar
78 Burke FM, McCormack N, Rindi S, Speziale P, Foster TJ. Fibronectin-binding protein B variation in Staphylococcus aureus. BMC Microbiol.10,160 (2010).Crossref, Medline, Google Scholar
79 McCarthy AJ, Lindsay JA. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol.10,173 (2010).▪ Describes the genetic variation in S. aureus surface and immune evasion genes between strains and the implications for vaccine development.Crossref, Medline, Google Scholar
80 Dreisbach A, Hempel K, Buist G, Hecker M, Becher D, van Dijl JM. Profiling the surfacome of Staphylococcus aureus.Proteomics10,3082–3096 (2010).Crossref, Medline, CAS, Google Scholar
81 Ziebandt AK, Kusch H, Degner M et al. Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics10,1634–1644 (2010).Crossref, Medline, CAS, Google Scholar
82 van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on β-hemolysin-converting bacteriophages. J. Bacteriol.188,1310–1315 (2006).Crossref, Medline, CAS, Google Scholar
83 Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. Anti-opsonic properties of staphylokinase. Microbes Infect.7,476–484 (2005).Crossref, Medline, CAS, Google Scholar
84 Foster TJ. Immune evasion by staphylococci. Nat. Rev. Microbiol.3,948–958 (2005).Crossref, Medline, CAS, Google Scholar
85 Haupt K, Reuter M, van den Elsen J et al. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement factor H and C3b. PLoS Pathog.4,E1000250 (2008).Crossref, Medline, Google Scholar
86 Jongerius I, Kohl J, Pandey MK et al. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med.204,2461–2471 (2007).Crossref, Medline, CAS, Google Scholar
87 Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc α RI binding and serum killing of bacteria. J. Immunol.174,2926–2933 (2005).Crossref, Medline, CAS, Google Scholar
88 Itoh S, Hamada E, Kamoshida G et al. Staphylococcal superantigen-like protein 10 (SSL10) binds to human immunoglobulin G (IgG) and inhibits complement activation via the classical pathway. Mol. Immunol.47,932–938 (2010).Crossref, Medline, CAS, Google Scholar
89 Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun.66,5183–5189 (1998).Crossref, Medline, CAS, Google Scholar
90 Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol.17,59–65 (2009).Crossref, Medline, CAS, Google Scholar
91 Schaffer AC, Lee JC. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents32,S71–S78 (2008).Crossref, Medline, CAS, Google Scholar
101 US NIH clinical trials registry and results database. www.clinicaltrials.govGoogle Scholar

Vol. 3, No. 9

Metrics

Downloaded 253 times

History

Published online 13 September 2011

Published in print September 2011

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download